KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Accounts Payables (2016 - 2025)

Historic Accounts Payables for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $2.0 million.

  • TherapeuticsMD's Accounts Payables fell 2849.54% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 2849.54%. This contributed to the annual value of $2.1 million for FY2024, which is 3210.98% down from last year.
  • As of Q3 2025, TherapeuticsMD's Accounts Payables stood at $2.0 million, which was down 2849.54% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Accounts Payables registered a high of $20.8 million during Q1 2022, and its lowest value of $696000.0 during Q3 2023.
  • In the last 5 years, TherapeuticsMD's Accounts Payables had a median value of $2.8 million in 2024 and averaged $7.3 million.
  • In the last 5 years, TherapeuticsMD's Accounts Payables surged by 45873.11% in 2022 and then tumbled by 9479.94% in 2023.
  • TherapeuticsMD's Accounts Payables (Quarter) stood at $3.4 million in 2021, then surged by 458.73% to $18.8 million in 2022, then crashed by 83.38% to $3.1 million in 2023, then plummeted by 32.11% to $2.1 million in 2024, then decreased by 5.27% to $2.0 million in 2025.
  • Its Accounts Payables stands at $2.0 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.8 million for Q1 2025.